Brilinta

Brilinta Indications/Uses

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
60 mg: History of Myocardial Infarction (at least one year ago): Brilinta, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with a history of myocardial infarction (MI) (MI occurred at least one year ago), and a high risk of developing an atherothrombotic event (see "Dosage & Administration" and "Pharmacology: Pharmacodynamics under Actions").
Coronary Artery Disease, Type 2 Diabetes Mellitus and History of Percutaneous Coronary Intervention: Brilinta, co-administered with low-dose acetylsalicylic acid (ASA: 75-150mg), is indicated to reduce the risk of a first myocardial infarction or stroke in patients with Coronary Artery Disease (CAD), Type 2 Diabetes Mellitus (DM) and a history of percutaneous coronary intervention (PCI), who are also at high risk of developing an atherothrombotic events (see "Dosage & Administration", "Precautions" and "Pharmacology: Pharmacodynamics under Actions").
90 mg: Acute Coronary Syndrome or a History of Myocardial Infarction: Brilinta, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Acute Ischemic Stroke or Transient Ischemic Attack (TIA): BRILINTA is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
For further information, refer to "Pharmacology: Pharmacodynamics under Actions".
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in